J & J ’ s Evarrest fibrin sealant patch wins expanded indication for hemostasis

Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon said today that the FDA approved an expanded indication for its Evarrest fibrin sealant patch as an supplementary hemostat. With the expanded indication, the patch can be used with manual compression as an adjunct to hemostasis in adult surgery patients, when standard surgical techniques to control bleeding such as suture or ligature are ineffective. The fibrin sealant patch uses biologics to rapidly stop problematic bleeding while a patient is undergoing surgery. The drug device reacts human thrombin and fibrinogen to form a fibrin clot, providing a structure for clot formation. Get the full story at our sister site, Drug Delivery Business News. The post J&J’s Evarrest fibrin sealant patch wins expanded indication for hemostasis appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Drug-Device Combinations Food & Drug Administration (FDA) Regulatory/Clearance Surgical Ethicon Johnson & Johnson Source Type: news